Top Tech Companies (2,061)
Don't see your company?
Create a company profile
Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
CBA Pharma manufactures, markets, licenses, and distributes drugs for medical oncology community.
Stability Biologics, a provider of human tissue and bone graft products
Sujana Biotech develops novel therapeutics for inflammatory and vascular disorders.
OrganaBio is a Miami-based CDMO that manufactures clinical (cGMP) grade cells for cancer immunotherapy and regenerative medicine drug developers. OrganaBio’s vision is to accelerate the development of these drugs by giving developers access to (i) fresh and scalable tissue supplies; (ii) cell isolation, purification, expansion, and characterization services; (iii) process development services; and (iv) clinical-grade manufacturing services. At OrganaBio, we empower our customers’ people, process, and products on their journey to commercialization. Our team is comprised of highly motivated individuals who thrive in a fast-paced environment and are adept (and like) to deal with different tasks within a workweek.
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics (using mammalian and microbial systems), mRNA, pDNA, viral vector and cell therapy products, from pre-clinical to commercial production, including our proprietary CHEF1TM Expression System for efficient protein production with CHO cells. Our company DNA drives us to provide innovative solutions to partner with our customers in helping them reach their goals and accelerate their projects at our cGMP-compliant facilities in the US, Europe and Japan, as well as to facilitate approval and manage spending during the product lifecycle. We forge exceptionally strong partnerships with our customers and we never lose sight of our commitment to deliver reliable and compliant drug substance. Visit www.agcbio.com to learn more.
Scout Bi is a biotechnology company that specializes in veterinary, animal health, and gene therapy.
Septerna is on a mission to make the promise of future GPCR medicines a reality for patients. Combining the latest advances in biochemical, structural and computational drug discovery approaches, we have built an industrialized platform to precisely control and modulate GPCR biology and pharmacology to discover and develop new high-impact medicines. With our Native Complex™ platform, we are opening a new frontier in GPCR small molecule discovery technologies to expand the druggable GPCR landscape. We are always looking for talented scientists, drug hunters, and business professionals to join our mission to launch a new era of GPCR medicines. If you’re passionate about innovation, energized by teamwork, and fueled by the desire to change patient lives, join us and become a part of the Septerna story!
Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh.
Oragenics develops oral probiotic products and antibiotics for humans and companion pets.
Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day. Community Guidelines: https://bit.ly/39x9gqy
At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.
TissueNetix is a biotechnology company.
BioSTL builds regional capacity and fosters collaborative efforts to advance innovation,
Qvella™ is a clinical diagnostics company with the goal to provide microbiology results in minutes. Providing clinicians with actionable information in clinically relevant time frames – minutes vs. hours or days – has the potential to revolutionize patient outcomes and reduce healthcare costs. Qvella's Field Activated Sample Treatment (FAST-Technology™) technologies include a novel sample treatment method and unique e-Lysis™ which can be combined in a fully-automated workflow that enables rapid isolation and concentration of viable infectious organisms from complex samples including whole blood.
Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale. In doing so, Pluristyx effectively decouples the hassles of expansion and banking from differentiation and product development, allowing early-stage companies to focus precious resources on therapeutic application rather than manufacturing hurdles, with the goal of advancing promising laboratory discoveries into patients. Pluristyx has a developed a proprietary footprint-free method to generate induced Pluripotent Stem Cells (iPSCs) from clinically-relevant starting material. Pluristyx iPSCs are manufactured at scale and cryopreserved at high-density in a Ready-to-Differentiate® (RTD®) format that can be immediately thawed for downstream differentiation without the need for additional expansion. Pluristyx also provides the consulting and process development support required to incorporate these RTD®-iPSCs into existing workflows to accelerate product development and clinical translation. In October, 2022 Pluristyx announced a merger with panCELLa. Pluristyx today offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.
NovaRx Corporation is a clinical-stage biopharmaceutical company.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,700 people across 41 countries.
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Our pipeline includes two investigational oral SYK inhibitors, entospletinib and lanraplenib, which are being developed to treat acute myeloid leukemia (AML). Together the compounds have the potential to target mutations present in more than two-thirds of patients with AML. We are also advancing an oral CDK9 inhibitor, KB-0742, to treat patients with solid tumors addicted to oncogenic transcription factor activity. KB-0742 is the first investigational medicine from our internal discovery platform to enter the clinic. Beyond these three investigational compounds, we are progressing additional discovery programs, including one focused on the MYC TRN and another focused on the AR TRN. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
Nereus Pharmaceuticals engages in the discovery and development of therapeutics for the treatment of infectious diseases and inflammation.
